P. I. Kulakova
P. I. Kulakova has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Galina V. Lukina
V.A. Nasonova Research Institute of Rheumatology
3 shared publications - Alexander A. Novikov
A.S. Loginov Moscow Clinical Scientific Center
2 shared publications - Elena N. Aleksandrova
A. S. Loginov Moscow Clinical Scientific Center
2 shared publications - M. A. Borisova
A.S. Loginov Moscow Clinical Scientific Center
2 shared publications A. A. Novikov
Moscow Clinical Scientific and Practical Centre n. a. A. S. Loginov
1 shared publication- A. G. Klimets
Moscow Clinical Scientific and Practical Centre n. a. A. S. Loginov
1 shared publication
Latest Publications
- 24 June 2026
- Published by Alfmed LLC in Medical alphabet
- No. 12
Evaluation of the possibility of using fecal calprotectin for the diagnosis of inflammatory bowel diseases in patients with ankylosing spondylitis
The aim . To evaluate the possibility of using fecal calprotectin levels for early diagnosis of inflammatory bowel diseases in patients with AS in real clinical practice. Materials and methods . The analysis included 70 patients with a confirmed diagnosis of AS over the age of 18: 52 men (74.3 %) and 18 women (25.7 %), aged 47.4±8.8 years, with a disease duration of 19.6±7.9 years. All patients underwent blood tests (ESR, CRP, HLAB 27 antigen levels), esophagogastroduodenoscopy and colonoscopy, quantitative analysis of the fecal calprotectin levels using the method of lateral immunochromatography with the BUHLMANN Quantum Blue rapid test (standart range: 100–1800 μg/g). Results . All patients had high disease activity: BASDAI was 5.4±1.4, ASDAS CRP – 3.6±0.8. IBD was diagnosed in 18 cases (25.7 %). In 77 % of patients with AS, the FC level exceeded 100 μg/g, and in 28 % it exceeded 1800 μg/l. The FC level was more than 1000 μg/g in 63 %. In patients with IBD, the FC level was more than 100 μg/g, and the average FC level was higher in patients with IBD (1141.3 μg/g) than without IBD (787 μg/g). No active IBD was detected in all patients with FC levels less than 300 μg/g of feces. FC levels correlated with CRP (r=0.366) and ESR (r=0.366) (pConclusion . Patients with AS and IBD had higher FC levels than patients without IBD. Normal FC levels in patients with AS indicate the absence of intestinal inflammation. There was also a correlation between increased FC levels and the severity of AS. According to the study, measuring fecal calprotectin levels may be useful for detecting intestinal inflammation at an early stage.
- 24 June 2026
- Published by Alfmed LLC in Medical alphabet
- No. 12
Evaluation of the possibility of using fecal calprotectin for the diagnosis of inflammatory bowel diseases in patients with ankylosing spondylitis
The aim . To evaluate the possibility of using fecal calprotectin levels for early diagnosis of inflammatory bowel diseases in patients with AS in real clinical practice. Materials and methods . The analysis included 70 patients with a confirmed diagnosis of AS over the age of 18: 52 men (74.3 %) and 18 women (25.7 %), aged 47.4±8.8 years, with a disease duration of 19.6±7.9 years. All patients underwent blood tests (ESR, CRP, HLAB 27 antigen levels), esophagogastroduodenoscopy and colonoscopy, quantitative analysis of the fecal calprotectin levels using the method of lateral immunochromatography with the BUHLMANN Quantum Blue rapid test (standart range: 100–1800 μg/g). Results . All patients had high disease activity: BASDAI was 5.4±1.4, ASDAS CRP – 3.6±0.8. IBD was diagnosed in 18 cases (25.7 %). In 77 % of patients with AS, the FC level exceeded 100 μg/g, and in 28 % it exceeded 1800 μg/l. The FC level was more than 1000 μg/g in 63 %. In patients with IBD, the FC level was more than 100 μg/g, and the average FC level was higher in patients with IBD (1141.3 μg/g) than without IBD (787 μg/g). No active IBD was detected in all patients with FC levels less than 300 μg/g of feces. FC levels correlated with CRP (r=0.366) and ESR (r=0.366) (pConclusion . Patients with AS and IBD had higher FC levels than patients without IBD. Normal FC levels in patients with AS indicate the absence of intestinal inflammation. There was also a correlation between increased FC levels and the severity of AS. According to the study, measuring fecal calprotectin levels may be useful for detecting intestinal inflammation at an early stage.
- 27 January 2026
- Published by Alfmed LLC in Medical alphabet
- Vol. 1 (34)
Inflammatory bowel disease-associated antibodies in ankylosing spondylitis: relationship with clinical and laboratory markers of inflammation
Background/Purpose. To study the relationship between levels of antibodies associated with inflammatory bowel diseases (IBD) and inflammatory markers in ankylosing spondylitis (AS). Materials and methods. The sera of 44 healthy donors (HD) and 51 patients with AS were studied: 40 men, 11 women aged 44.0 (34.0–49.0) years with a disease duration of 12.0 (5.0–20.0) years, high disease activity (BASDAI – 5.3; 4.5–6.4; ASDAS ESR – 3.6; 3.0–4.4; ASDAS CRP – 3.7; 2.8–4.5). IBD was diagnosed in 22 % of patients with AS. IgG/IgA antibodies to S. cerevisiae (ASCA), IgG/IgA antibodies to glycoprotein 2 (GP2), IgG antibodies to cathepsin G, elastase, serum calprotectin (sCP), interleukin-6 (IL-6) were determined by ELISA. Results. Patients with AS without IBD and AS with IBD had higher levels of IgA ASCA, IgA aGP2, and elastase antibodies than HD (4.5; 2.6–6.4 U/ml and 4.9; 3.7–7.3 U/ml vs 1.9; 0.6–2.6 U/ml, p=0.0008, p=0.001; 1.2; 0.8–5.5 U/ml and 1.2; 0.9–11.8 U/ml vs 0.7; p=0.007, p=0.02; 8.2; 5.9–9.9 U/ml and 9.1; 8.5–10.5 U/ml vs 5.6; 4.7–8.3 U/ml, p=0.01, p=0.003). The concentration of antibodies to cathepsin G was higher in AS with IBD compared to AS without IBD (0.8; 0.5–1.0 U/ml vs 0.4; 0.3–0.6 U/ml, p=0.02). The levels of IgA ASCA correlated with IL-6 (r=0.3), IgA aGP2 – with sCP (r=0.3), antibodies to elastase – with ESR (r=0.4), antibodies to cathepsin G – with ESR (r=0.4) and BASDAI (r=0.4) (pConclusion. Elevated levels of IgA ASCA, IgA aGP2, and anti-elastase antibodies in AS without IBD are similar to those in AS with IBD. Hyperproduction of IgA ASCA, IgA aGP2, anti-elastase antibodies, and cathepsin G reflects the inflammatory activity of AS.
- 27 January 2026
- Published by Alfmed LLC in Medical alphabet
- Vol. 1 (34)
Inflammatory bowel disease-associated antibodies in ankylosing spondylitis: relationship with clinical and laboratory markers of inflammation
Background/Purpose. To study the relationship between levels of antibodies associated with inflammatory bowel diseases (IBD) and inflammatory markers in ankylosing spondylitis (AS). Materials and methods. The sera of 44 healthy donors (HD) and 51 patients with AS were studied: 40 men, 11 women aged 44.0 (34.0–49.0) years with a disease duration of 12.0 (5.0–20.0) years, high disease activity (BASDAI – 5.3; 4.5–6.4; ASDAS ESR – 3.6; 3.0–4.4; ASDAS CRP – 3.7; 2.8–4.5). IBD was diagnosed in 22 % of patients with AS. IgG/IgA antibodies to S. cerevisiae (ASCA), IgG/IgA antibodies to glycoprotein 2 (GP2), IgG antibodies to cathepsin G, elastase, serum calprotectin (sCP), interleukin-6 (IL-6) were determined by ELISA. Results. Patients with AS without IBD and AS with IBD had higher levels of IgA ASCA, IgA aGP2, and elastase antibodies than HD (4.5; 2.6–6.4 U/ml and 4.9; 3.7–7.3 U/ml vs 1.9; 0.6–2.6 U/ml, p=0.0008, p=0.001; 1.2; 0.8–5.5 U/ml and 1.2; 0.9–11.8 U/ml vs 0.7; p=0.007, p=0.02; 8.2; 5.9–9.9 U/ml and 9.1; 8.5–10.5 U/ml vs 5.6; 4.7–8.3 U/ml, p=0.01, p=0.003). The concentration of antibodies to cathepsin G was higher in AS with IBD compared to AS without IBD (0.8; 0.5–1.0 U/ml vs 0.4; 0.3–0.6 U/ml, p=0.02). The levels of IgA ASCA correlated with IL-6 (r=0.3), IgA aGP2 – with sCP (r=0.3), antibodies to elastase – with ESR (r=0.4), antibodies to cathepsin G – with ESR (r=0.4) and BASDAI (r=0.4) (pConclusion. Elevated levels of IgA ASCA, IgA aGP2, and anti-elastase antibodies in AS without IBD are similar to those in AS with IBD. Hyperproduction of IgA ASCA, IgA aGP2, anti-elastase antibodies, and cathepsin G reflects the inflammatory activity of AS.
- 13 December 2021
- Published by Alfmed LLC in Medical alphabet
- No. 33,p. 16-19
Role of serum calprotectin in diagnosis of inflammatory bowel diseases in patients with ankylosing spondylitis (preliminary results)
Background. Patients with inflammatory bowel diseases (IBD) often have lesions of the musculoskeletal system, which is an extra-intestinal manifestation and mainly belongs to the group of seronegative spondyloarthritis (SPA). Ankylosing spondylitis (AS) is one of the main forms of diseases from the group of spondyloarthritis, associated with IBD. The frequency of AS in patients with IBD is of interest for elucidating the general pathophysiology of diseases. Colonoscopy is required to diagnose intestinal pathology. Colonoscopy in patients with AS to detect IBD, especially in the absence of intestinal symptoms, is very diffcult. Mainly for the diagnosis of IBD, the defnition of fecal calprotectin is used. Recently, there has been an interest in serum calprotectin, an increase in which is associated with a higher activity of the disease and is a marker of the intensity of inflammation in the intestine. However, there is currently no consensus on the clinical signifcance for serum calprotectin.The aim. To evaluate the role of serum calprotectin in diagnosis of inflammatory bowel disease in patients with ankylosing spondylitis.Materials and methods. In the analysis were included 50 patients with AS, fulflling the modifed New York criteria, among them were 36 (72%) men and 14 (28%) women, the mean age of patients was 42.5 ± 9.9, mean disease duration was 13.4 ± 8.7 years. All patients were examined with ESR, CRP, FC (range: 100–1800 µg/g), esophagogastroduodenoscopy, colonoscopy and quantitative analysis of the SC level using ELISA (Buhlmann MRP8/14 ELISA, range: 0.4–3.9 µg/ml).Results. All patients had a high disease activity, mean BASDAI was 5.3 ± 1.8, mean ASDAS CRP was 3.7 ± 1.01, mean ASDAS ESR was 3.6 ± 1.01. 78% patients had high FC level (more than 100 µg/g), while only 18% patients had an increase of SC level. IBD were diagnosed in 11 cases: 6 (12%) patients with CD and 5 (10%) patients with UC, in the remaining cases (78%) was no intestinal pathology. Only two patients with IBD had a high SC level. SC level was more correlated with ESR (r = 0.5) and CRP (r = 0.5) (p < 0.05) levels, than with FC level (r = 0.4) (p < 0.05).Conclusion. The results have shown that there was currently insuffcient data to assess the possibility of using SC in the diagnosis of IBD in patients with AS. There was a signifcant association between the SC, CRP and ESR, but not fecal calprotectin. Potentially SC may be more representative for systemic inflammation than intestinal inflammation.
- 13 December 2021
- Published by Alfmed LLC in Medical alphabet
- No. 33,p. 16-19
Role of serum calprotectin in diagnosis of inflammatory bowel diseases in patients with ankylosing spondylitis (preliminary results)
Background. Patients with inflammatory bowel diseases (IBD) often have lesions of the musculoskeletal system, which is an extra-intestinal manifestation and mainly belongs to the group of seronegative spondyloarthritis (SPA). Ankylosing spondylitis (AS) is one of the main forms of diseases from the group of spondyloarthritis, associated with IBD. The frequency of AS in patients with IBD is of interest for elucidating the general pathophysiology of diseases. Colonoscopy is required to diagnose intestinal pathology. Colonoscopy in patients with AS to detect IBD, especially in the absence of intestinal symptoms, is very diffcult. Mainly for the diagnosis of IBD, the defnition of fecal calprotectin is used. Recently, there has been an interest in serum calprotectin, an increase in which is associated with a higher activity of the disease and is a marker of the intensity of inflammation in the intestine. However, there is currently no consensus on the clinical signifcance for serum calprotectin.The aim. To evaluate the role of serum calprotectin in diagnosis of inflammatory bowel disease in patients with ankylosing spondylitis.Materials and methods. In the analysis were included 50 patients with AS, fulflling the modifed New York criteria, among them were 36 (72%) men and 14 (28%) women, the mean age of patients was 42.5 ± 9.9, mean disease duration was 13.4 ± 8.7 years. All patients were examined with ESR, CRP, FC (range: 100–1800 µg/g), esophagogastroduodenoscopy, colonoscopy and quantitative analysis of the SC level using ELISA (Buhlmann MRP8/14 ELISA, range: 0.4–3.9 µg/ml).Results. All patients had a high disease activity, mean BASDAI was 5.3 ± 1.8, mean ASDAS CRP was 3.7 ± 1.01, mean ASDAS ESR was 3.6 ± 1.01. 78% patients had high FC level (more than 100 µg/g), while only 18% patients had an increase of SC level. IBD were diagnosed in 11 cases: 6 (12%) patients with CD and 5 (10%) patients with UC, in the remaining cases (78%) was no intestinal pathology. Only two patients with IBD had a high SC level. SC level was more correlated with ESR (r = 0.5) and CRP (r = 0.5) (p < 0.05) levels, than with FC level (r = 0.4) (p < 0.05).Conclusion. The results have shown that there was currently insuffcient data to assess the possibility of using SC in the diagnosis of IBD in patients with AS. There was a signifcant association between the SC, CRP and ESR, but not fecal calprotectin. Potentially SC may be more representative for systemic inflammation than intestinal inflammation.